Artelo Biosciences Inc (ARTL NASDAQ) stock market data APIs
$0.7373
0(0%)
as of August 12, 2026
Try our APIs with
free plan!
Artelo Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Prev. Close
0.7373
Open
0.7381
High
0.754
Low
0.706
52 wk Range
0.705-31.65
Market Cap
2 555 K
Shares Outstanding
3 486 K
EPS
-16.83
Beta
-0.072
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Artelo Biosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Artelo Biosciences Inc data using free add-ons & libraries
Get Artelo Biosciences Inc Fundamental Data
Artelo Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -7 440 756
- Earnings Per Share: -29
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Artelo Biosciences Inc News
New
Artelo Biosciences Enrolls First Patient In Phase 2 Glaucoma Study Of ART27.13
(RTTNews) - Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced the enrollment of the first patient in the Phase 2 DREAM study evalu...
Artelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure
(RTTNews) - Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucom...
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biol...
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating l...
Get Artelo Biosciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
